Forging ahead with its new three-year business plan, Chugai Pharmaceutical enjoyed rosy earnings in the first half of 2019, bolstered by the outperformance of the Hemlibra (emicizumab) hemophilia drug and its I/O star Tecentriq (atezolizumab). But with a biosimilar onslaught…
REGULATORY
Nesp Biosame to Join NHI Price List, Launch Due by September; Symbicort Generics, Teribone AG Skip Listing
The Ministry of Health, Labor and Welfare (MHLW) will add a slew of generics to the NHI price list on June 14, including the so-called “biosame” version of the Nesp (darbepoetin alfa) renal anemia drug, according to the official gazette…
To read the full story
Related Article
- Daiichi Sankyo Espha Rolls Out AstraZeneca’s 3 Cancer AGs; Gx Onslaught for Lonasen, Urief
June 14, 2019
- Nesp Biosame Priced at 62.8-69.2% of Originator
June 14, 2019
- Toa, Nipro, Nihon Generic Codeveloped Symbicort Copies, Launch Timing Unclear
February 18, 2019
- Japan Approves Symbicort Generics, Asthma Drug Stalwart Could Face Competition in June
February 15, 2019
REGULATORY
- Rituxan’s Orphan Status Dropped for Rare Blood Disorder
August 16, 2019
- Japan’s 1st Forteo Biosimilar Could Get Listed in November
August 16, 2019
- First “Post-Nesp” Renal Anemia Med Could Land Japan Approval in September
August 16, 2019
- AbbVie’s Venetoclax Up for Review on Aug. 23; Tecentriq’s Breast Cancer Use, 2nd Biosimilars Also on Agenda
August 16, 2019
- Japan OKs Zetia Generic, Possibly AG, towards December Listing; No Entry for Lyrica This Time
August 16, 2019
Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
In 2011 the Japanese pharmaceutical industry was rocked when a whistleblower exposed the falsification of trial data for the drug Diovan, the blockbuster blood pressure drug manufactured by pharma giant Novartis. The ensuing investigation led to the arrest of one…